Sanofi ADR (SNY : NASDAQ)
Common Stock
$18.27
USD
-21.24 (-53.76%)
Last updated: 2026-10-06
Follow SNY
SNY
Sanofi ADR
WealthAwesomePerformance
1 Day
+0.13%
1 Week
-2.90%
1 Month
-10.58%
YTD
-13.43%
Key Statistics
Market Cap
$94.67B
52W High
$49.91
52W Low
$39.18
P/E Ratio
20.79
50 Day MA
$43.39
200 Day MA
$45.05
Beta
0.28
Dividend Yield
10.32%
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/6/2026 | $40.05 | $40.05 | $39.24 | $39.56 | $39.56 | 3,051,900 |
| 10/5/2026 | $39.83 | $39.88 | $39.18 | $39.51 | $39.51 | 3,797,509 |
| 10/2/2026 | $39.58 | $40.07 | $39.50 | $39.92 | $39.92 | 4,335,000 |
| 10/1/2026 | $41.85 | $41.88 | $40.64 | $40.67 | $40.67 | 6,682,900 |
| 9/30/2026 | $41.35 | $41.38 | $40.96 | $41.23 | $41.23 | 4,304,100 |
| 9/29/2026 | $40.58 | $40.80 | $40.40 | $40.74 | $40.74 | 3,040,200 |
| 9/28/2026 | $40.77 | $41.24 | $40.77 | $41.18 | $41.18 | 2,173,700 |
| 9/25/2026 | $40.89 | $41.12 | $40.66 | $41.11 | $41.11 | 2,216,900 |
| 9/24/2026 | $41.23 | $41.61 | $40.91 | $40.94 | $40.94 | 3,069,900 |
| 9/23/2026 | $41.85 | $41.96 | $41.41 | $41.66 | $41.66 | 3,838,000 |
Analyst Price Targets
Based on 10 analysts covering SNY · as of Oct 5, 2026
Wall Street analysts forecast SNY stock price to rise 194.0% over the next 12 months.
Consensus
Buy4.00 / 5.00
Avg. Target
US$53.72
+194.0% Upside
Current Price
US$18.27
Last close
Analyst Breakdown (10 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SNY's historical volatility
30-Day Vol
16.7%
Annualized
90-Day Vol
24.3%
Annualized
Trend (90d)
-44.7%
Annualized drift
90d Mean
US$33.73
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$37.51 | US$35.42 – US$39.73 |
| 60 trading days | US$35.57 | US$32.79 – US$38.58 |
| 90 trading days | US$33.73 | US$30.53 – US$37.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Sanofi ADR
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Financials
- Revenue (TTM)
- $48.92B
- EBITDA
- $13.54B
- Profit Margin
- 8.09%
- ROE (TTM)
- 5.71%
- EPS (Diluted)
- 1.90
- Book Value
- 33.60
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About SNY.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| QRVO | Qorvo Inc | $2070.39 | +1713.43% |
| SUGP | SU Group Holdings Limited Ordinary Shares | $2.44 | +511.43% |
| COLA | Columbus Acquisition Corp Ordinary Shares | $5.16 | +178.92% |
| OLB | OLB Group Inc | $0.41 | +117.85% |
| MOBX | Mobix Labs Inc | $1.12 | +72.28% |
| VCIG | VCI Global Limited Ordinary Share | $1.41 | +54.77% |
| XHLD | TEN Holdings, Inc. Common Stock | $0.62 | +51.58% |
| IPDN | Professional Diversity Network Inc | $4.61 | +48.71% |
SNY.US news timeline
1 article covering SNY.US, most recent first
Latest